Oruka Therapeutics (ORKA) Competitors $20.31 -0.45 (-2.17%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends ORKA vs. QDEL, NEOG, CLDX, NTLA, MYGN, TKNO, ACHV, VNRX, CDIO, and ICCCShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Alpha Teknova (TKNO), Achieve Life Sciences (ACHV), VolitionRx (VNRX), Cardio Diagnostics (CDIO), and ImmuCell (ICCC). These companies are all part of the "diagnostic substances" industry. Oruka Therapeutics vs. QuidelOrtho Neogen Celldex Therapeutics Intellia Therapeutics Myriad Genetics Alpha Teknova Achieve Life Sciences VolitionRx Cardio Diagnostics ImmuCell Oruka Therapeutics (NASDAQ:ORKA) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability. Which has more volatility and risk, ORKA or QDEL? Oruka Therapeutics has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Does the media favor ORKA or QDEL? In the previous week, Oruka Therapeutics had 8 more articles in the media than QuidelOrtho. MarketBeat recorded 13 mentions for Oruka Therapeutics and 5 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 1.33 beat Oruka Therapeutics' score of 0.46 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral QuidelOrtho 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ORKA or QDEL? 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 1.0% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, ORKA or QDEL? Oruka Therapeutics has higher earnings, but lower revenue than QuidelOrtho. Oruka Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$5.34M-$6.26-3.24QuidelOrtho$2.82B1.07-$10.10M-$27.90-1.61 Is ORKA or QDEL more profitable? Oruka Therapeutics has a net margin of 0.00% compared to QuidelOrtho's net margin of -66.25%. QuidelOrtho's return on equity of 4.24% beat Oruka Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -24.96% -21.22% QuidelOrtho -66.25%4.24%2.17% Do analysts rate ORKA or QDEL? Oruka Therapeutics currently has a consensus price target of $43.17, suggesting a potential upside of 112.54%. QuidelOrtho has a consensus price target of $53.43, suggesting a potential upside of 19.15%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than QuidelOrtho.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13QuidelOrtho 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Does the MarketBeat Community favor ORKA or QDEL? QuidelOrtho received 431 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 67.17% of users gave QuidelOrtho an outperform vote. CompanyUnderperformOutperformOruka TherapeuticsOutperform Votes13100.00% Underperform VotesNo VotesQuidelOrthoOutperform Votes44467.17% Underperform Votes21732.83% SummaryOruka Therapeutics beats QuidelOrtho on 11 of the 18 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$726.58M$2.51B$5.14B$9.08BDividend YieldN/A0.73%5.09%4.23%P/E Ratio-3.246.0789.7417.16Price / SalesN/A75.121,117.09117.04Price / CashN/A15.0543.1037.86Price / Book0.583.284.784.78Net Income-$5.34M$29.98M$120.31M$225.60M7 Day Performance-7.43%-1.55%-1.92%-1.23%1 Month Performance-2.12%6.18%13.65%0.46%1 Year PerformanceN/A-20.93%28.34%15.24% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics3.013 of 5 stars$20.31-2.2%$43.17+112.5%N/A$726.58MN/A-3.24N/AAnalyst ForecastNews CoverageGap DownHigh Trading VolumeQDELQuidelOrtho4.1092 of 5 stars$42.67+3.2%$53.43+25.2%-39.2%$2.87B$3.00B-1.577,100Gap UpNEOGNeogen3.4623 of 5 stars$11.96-1.6%$17.50+46.3%-41.8%$2.59B$912.20M-110.452,640Analyst ForecastNews CoverageCLDXCelldex Therapeutics2.6339 of 5 stars$26.37+3.8%$62.25+136.1%-33.5%$1.75B$6.88M-9.89160Analyst ForecastNews CoverageNTLAIntellia Therapeutics4.224 of 5 stars$13.50+4.7%$54.94+306.9%-59.7%$1.37B$36.28M-2.37600MYGNMyriad Genetics4.4439 of 5 stars$14.19-1.7%$24.27+71.1%-34.7%$1.29B$823.60M-11.102,700TKNOAlpha Teknova0.4718 of 5 stars$8.84+10.1%$5.00-43.4%+124.1%$471.26M$36.68M-11.73240Gap UpACHVAchieve Life Sciences2.0087 of 5 stars$4.11+0.2%$14.80+260.1%+6.6%$141.34MN/A-3.6320VNRXVolitionRx1.7495 of 5 stars$0.67+18.6%$3.75+459.7%+4.3%$62.09M$770,000.00-1.5780Gap UpCDIOCardio Diagnostics2.6517 of 5 stars$1.17-7.5%$2.00+71.7%-58.0%$47.11M$35,688.000.007Gap UpHigh Trading VolumeICCCImmuCellN/A$4.61-6.3%N/A-5.4%$41.08M$23.84M-9.8475 Related Companies and Tools Related Companies QDEL Competitors NEOG Competitors CLDX Competitors NTLA Competitors MYGN Competitors TKNO Competitors ACHV Competitors VNRX Competitors CDIO Competitors ICCC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORKA) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORKA Stock Alerts